Semaglutid

Semaglutide is a GLP-1 receptor agonist and the approved gold standard of the first generation of weight-loss injections. It reduces appetite and "food noise" and stabilises blood sugar; evidence level 4.

How does semaglutide work?

Semaglutide mimics the gut hormone GLP-1: it signals the pancreas to release insulin, slows gastric emptying and dampens the hunger centre in the brain. In its modified form it stays active for about a week (instead of minutes for the natural hormone). The result is faster satiety with smaller portions and steadier blood sugar. This direct action on appetite and metabolism explains its clinical strength.

What is semaglutide used for?

Developed by Novo Nordisk for type 2 diabetes (Ozempic), it was later approved at higher doses for obesity (Wegovy) because of its strong weight-loss effect. In high-risk patients it additionally lowers cardiovascular events by roughly 20 %. For many users this means a reliable, well-studied route to sustained weight reduction. Want to save your dosing protocols? Create a free account.

What does the evidence say?

The STEP trials (Phase 3) demonstrated safety and efficacy in thousands of participants; approved by the FDA and EMA. The technological successor is tirzepatide (a dual agonist), followed by retatrutide (a triple agonist). To plan injection volumes safely, use the dosage calculator or check the FAQ.

Note: Educational information, not medical advice. Many of these substances are experimental and not approved for human use.